Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Stage IV Colon Cancer Patients Undergoing First-Line Chemotherapy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Nuvastatic™, Placebo.
- Who it may be relevant to
- Registry conditions: Fatigue, Colon Cancer. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- India
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Stage IV Colon Cancer Patients Undergoing First-Line Chemotherapy
Overview
The goal of this clinical trial is to evaluate whether Nuvastatic can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy. The main questions it aims to answer are: Does Nuvastatic significantly reduce cancer-related fatigue compared to placebo? Is Nuvastatic safe and well tolerated in this patient population? Researchers will compare Nuvastatic vs placebo to see if Nuvastatic improves fatigue scores and maintains an acceptable safety profile. Participants will: Receive Nuvastatic or placebo sachets (3 times per day) for 3 cycles of 20 days each (total \~60 treatment days). Continue their standard first-line chemotherapy regimen. Provide blood samples for biomarkers (CEA, CA-125) at Screening and End of Treatment. Complete patient diaries and fatigue assessments as per protocol.
Interventions
- Drug Nuvastatic™
1000mg Sachet, (1 sachet X 3 times a day) - Drug Placebo
1000mg sachet, (1 sachet X 3 times a day)
Primary outcome measures
- Changes in cancer-related fatigue in colon cancer patients undergoing first-line chemotherapy, assessed after treatment with Nuvastatic versus placebo. [Time frame: from screening up to 12 weeks]
- Changes in cancer-related fatigue in colon cancer patients undergoing first-line chemotherapy, assessed after treatment with Nuvastatic versus placebo. [Time frame: From Screening up to 12 weeks]
Secondary outcome measures (1)
- Overall QoL and functional improvement [Time frame: at baseline and at end of the study at 12 weeks]
Eligibility criteria
Inclusion criteria
- Male and female Patients who are ≥18 and ≤65 years of age, who are willing to voluntarily provide consent for participation in the study.
- Patients with colon cancer planned or scheduled to receive standard chemotherapy treatment for at least 3 cycles respectively.
- Patients must have a confirmed diagnosis of colon cancer as per standard guideline.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening.
- The patient has stable haemoglobin (≥ 9 g/dL) throughout the screening.
- Life expectancy ≥ 6 months, as per Investigator's judgment
- Patients with co-morbidities or medical conditions including Type 2 DM, hypertension and are deemed stable by the investigator can be included in the study
- At screening patients with stable fatigue, has a newly developed fatigue OR worsening of fatigue scoring as assessed by BFI should be included.
- Starting first-line chemo
Exclusion criteria
- Patients who have any untreated reversible medical condition which may cause fatigue (e.g. metabolic disturbance, infection, endocrine abnormalities) as per the Investigator's clinical judgment.
- Patients who have stage IV Disease
- Patients who have received concurrent stimulant medication (e.g. dextroamphetamine or methylphenidate) during the screening period or any medication which may interfere with study drug.
- Prior metastatic chemo, targeted/immunotherapy, severe comorbidities
- Female patients who are pregnant or breast-feeding.
- Patients with known hepatitis C virus, hepatitis B virus, HIV infection.
- Patients who have nausea and vomiting or any gastrointestinal disorder that is severe enough to interfere with study drug absorption in the opinion of the Investigator.
- Patients with uncontrolled pain, who in the opinion of the Investigator are not eligible for the study. '
- Patients with planned therapy or treatment with another investigational agent.
- Previous exposure to any investigational agent within 4 weeks prior to screening, or planned administration of an Investigational agent, other than as specified by this protocol, during the study period.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Supportive care
Study locations
India · 6 centers
- Department of Medical Oncology (In Charge - Oncology Unit) — Srikakulam
- Hanji Cancer Centre — Belagavi
- K.R. Hospital, Mysore Medical College & Research Institute — Mysuru
- Onco- Life Cancer — Satara
- Onco-Life Cancer Centre, Pvt. Ltd — Talegaon Dābhāde
- Avicenna Hospital — Lucknow
Identifiers
NCT: NCT07669519 · NUVA-CC-III-2025 · NatureCeuticals Sdn Bhd